Kerstin L. H.
- Country
- Germany
- Department
- Onkologie und Haematologie
Research Overview
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
- Evaluation of CDK4/6 Inhibitor Discontinuation in Metastatic HR+ HER2- Breast Cancer with Exemestane, Fulvestrant, Anastrozole, Letrozole, and Endocrine Therapy
Data & Insights
Has run more than one trial at 232 of 529 partner sites.
Specializations
Breast Cancer
Clinical research in early breast cancer, locally advanced breast cancer, and metastatic breast cancer with a strong focus on hormone receptor-positive, HER2-negative, and HER2-positive disease. Interest extends to triple-negative breast cancer, ESR1-mutated breast cancer, and high-risk recurrence settings, including adjuvant, neoadjuvant, and post-surgical treatment strategies.
- Endocrine therapy
- CDK4/6 inhibition
- Antibody-drug conjugates
- PI3K/AKT pathway targeting
- Immunotherapy combinations
The therapeutic landscape includes recurrence prevention, resistance after prior endocrine treatment, and biomarker-informed treatment selection in advanced and early-stage disease.
Non-Small Cell Lung Cancer
Research activity covers non-small cell lung cancer across resectable, locally advanced, and metastatic settings, including EGFR-mutated, ALK-positive, RET fusion-positive, KRAS G12C-mutant, and PD-L1-defined subgroups. The clinical focus also includes postoperative risk-adapted treatment and disease control after prior systemic therapy.
- Targeted therapy
- EGFR-directed treatment
- ALK inhibition
- RET inhibition
- Immune checkpoint blockade
Areas of interest include treatment for EGFR exon 20 insertion disease, atypical EGFR mutations, and molecularly selected patients after complete tumour resection.
Thoracic Malignancies
Clinical involvement extends to pleural mesothelioma and related thoracic cancers, with emphasis on systemic treatment options for unresectable disease and combination approaches integrating immunotherapy and chemotherapy.
- Pleural mesothelioma
- First-line systemic therapy
- Combination immunotherapy
- Platinum-based regimens
The therapeutic scope includes advanced thoracic disease where durable disease control and survival improvement remain central goals.
Colorectal Cancer
Research also covers colon cancer and metastatic colorectal cancer, with attention to postoperative risk assessment, residual disease, and treatment decisions guided by ctDNA status in stage II disease.
- Adjuvant therapy
- ctDNA-guided risk stratification
- Metastatic disease control
This area reflects interest in refining treatment intensity after resection and in managing advanced disease with post-procedural systemic strategies.
Hematologic Malignancies
Clinical research includes acute lymphoblastic leukemia, particularly Philadelphia chromosome-positive disease, with therapeutic interest in treatment pathways that incorporate tyrosine kinase inhibition and blinatumomab for molecularly defined leukemia.
- Ph+ ALL
- Tyrosine kinase inhibitors
- Blinatumomab-based therapy
The focus is on treatment selection in newly diagnosed disease and on optimizing disease control in patients with measurable molecular response.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.